Pharmacological management of attention deficit hyperactivity disorder in adults - PubMed

4 hours ago

ADHD is a neurodevelopmental disorder affecting 3-5% of adults, characterized by inattention, hyperactivity, or impulsivity.
Primary pharmacotherapies include psychostimulants (methylphenidate, dexamfetamine, lisdexamfetamine) and non-psychostimulants (atomoxetine).
In Australia, Pharmaceutical Benefits Scheme subsidy eligibility varies based on whether ADHD was diagnosed in childhood or adulthood.
Monitoring for physical (e.g., cardiac symptoms, appetite changes) and psychiatric (e.g., mood disturbances, psychosis) adverse effects is essential.
Pharmacological treatment should be part of a multidisciplinary approach, including psychological therapies and allied health support.

Hasty Briefsbeta